Benzinga··Vandana SinghImmunityBio Surges on Strong Q1 Revenue, But FDA Warning Clouds Outlook
ImmunityBio stock rallied 7% after reporting $44.2M in Q1 product revenue, up 168% YoY, despite FDA warning over Anktiva marketing claims.
IBRXAnktivaImmunityBio